|
| 36302175 | A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma. | Clin Cancer Res | 2023 |
| 36302175 | A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma. | Clin Cancer Res | 2023 |
| 37398992 | Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma. | Clin Cancer Res | 2023 |
| 37267580 | The Childhood Cancer Data Initiative: Using the Power of Data to Learn From and Improve Outcomes for Every Child and Young Adult With Pediatric Cancer. | J Clin Oncol | 2023 |
| 37398992 | Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma. | Clin Cancer Res | 2023 |
| 37267580 | The Childhood Cancer Data Initiative: Using the Power of Data to Learn From and Improve Outcomes for Every Child and Young Adult With Pediatric Cancer. | J Clin Oncol | 2023 |
| 33063919 | LRRC15 antibody-drug conjugates show promise as osteosarcoma therapeutics in preclinical studies. | Pediatr Blood Cancer | 2021 |
| 33289920 | SARC025 arms 1 and 2: A phase 1 study of the poly(ADP-ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma. | Cancer | 2021 |
| 33063919 | LRRC15 antibody-drug conjugates show promise as osteosarcoma therapeutics in preclinical studies. | Pediatr Blood Cancer | 2021 |
| 34561271 | Recent Advances in Pediatric Cancer Research. | Cancer Res | 2021 |
| 34818481 | New Horizons in the Treatment of Osteosarcoma. | N Engl J Med | 2021 |
| 34818481 | New Horizons in the Treatment of Osteosarcoma. | N Engl J Med | 2021 |
| 34561271 | Recent Advances in Pediatric Cancer Research. | Cancer Res | 2021 |
| 33289920 | SARC025 arms 1 and 2: A phase 1 study of the poly(ADP-ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma. | Cancer | 2021 |
| 32127464 | CDK9 Blockade Exploits Context-dependent Transcriptional Changes to Improve Activity and Limit Toxicity of Mithramycin for Ewing Sarcoma. | Mol Cancer Ther | 2020 |
| 32371575 | EWS-FLI1-regulated Serine Synthesis and Exogenous Serine are Necessary for Ewing Sarcoma Cellular Proliferation and Tumor Growth. | Mol Cancer Ther | 2020 |
| 32127464 | CDK9 Blockade Exploits Context-dependent Transcriptional Changes to Improve Activity and Limit Toxicity of Mithramycin for Ewing Sarcoma. | Mol Cancer Ther | 2020 |
| 32354737 | Targeting Hippo-Dependent and Hippo-Independent YAP1 Signaling for the Treatment of Childhood Rhabdomyosarcoma. | Cancer Res | 2020 |
| 32398945 | Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung. | Sarcoma | 2020 |
| 32464274 | Molecular mechanisms of Guadecitabine induced FGFR4 down regulation in alveolar rhabdomyosarcomas. | Neoplasia | 2020 |
| 32354737 | Targeting Hippo-Dependent and Hippo-Independent YAP1 Signaling for the Treatment of Childhood Rhabdomyosarcoma. | Cancer Res | 2020 |
| 32464274 | Molecular mechanisms of Guadecitabine induced FGFR4 down regulation in alveolar rhabdomyosarcomas. | Neoplasia | 2020 |
| 32398945 | Results of a Randomized, Double-Blinded, Placebo-Controlled, Phase 2.5 Study of Saracatinib (AZD0530), in Patients with Recurrent Osteosarcoma Localized to the Lung. | Sarcoma | 2020 |
| 32371575 | EWS-FLI1-regulated Serine Synthesis and Exogenous Serine are Necessary for Ewing Sarcoma Cellular Proliferation and Tumor Growth. | Mol Cancer Ther | 2020 |
| 30808861 | Glutamine synthetase is necessary for sarcoma adaptation to glutamine deprivation and tumor growth. | Oncogenesis | 2019 |
| 31222885 | Insights into pediatric rhabdomyosarcoma research: Challenges and goals. | Pediatr Blood Cancer | 2019 |
| 30808861 | Glutamine synthetase is necessary for sarcoma adaptation to glutamine deprivation and tumor growth. | Oncogenesis | 2019 |
| 31431459 | Targeting Glycolysis through Inhibition of Lactate Dehydrogenase Impairs Tumor Growth in Preclinical Models of Ewing Sarcoma. | Cancer Res | 2019 |
| 31427883 | Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016). | Sarcoma | 2019 |
| 31439578 | A Phase II Trial of Vandetanib in Children and Adults with Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor. | Clin Cancer Res | 2019 |
| 31439578 | A Phase II Trial of Vandetanib in Children and Adults with Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor. | Clin Cancer Res | 2019 |
| 31431459 | Targeting Glycolysis through Inhibition of Lactate Dehydrogenase Impairs Tumor Growth in Preclinical Models of Ewing Sarcoma. | Cancer Res | 2019 |
| 31427883 | Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016). | Sarcoma | 2019 |
| 31222885 | Insights into pediatric rhabdomyosarcoma research: Challenges and goals. | Pediatr Blood Cancer | 2019 |
| 29334376 | Positively selected enhancer elements endow osteosarcoma cells with metastatic competence. | Nat Med | 2018 |
| 29334376 | Positively selected enhancer elements endow osteosarcoma cells with metastatic competence. | Nat Med | 2018 |
| 29634688 | Corrigendum: Positively selected enhancer elements endow osteosarcoma cells with metastatic competence. | Nat Med | 2018 |
| 29634688 | Corrigendum: Positively selected enhancer elements endow osteosarcoma cells with metastatic competence. | Nat Med | 2018 |
| 28029307 | Surgical Management of Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Pediatric and Wildtype GIST Clinic. | J Clin Oncol | 2017 |
| 28350521 | Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis). | J Clin Oncol | 2017 |
| 28735378 | A phase I/II trial and pharmacokinetic study of mithramycin in children and adults with refractory Ewing sarcoma and EWS-FLI1 fusion transcript. | Cancer Chemother Pharmacol | 2017 |
| 28899971 | Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. | Clin Cancer Res | 2017 |
| 28674120 | Surveillance Recommendations for Children with Overgrowth Syndromes and Predisposition to Wilms Tumors and Hepatoblastoma. | Clin Cancer Res | 2017 |
| 29138631 | SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors. | Sarcoma | 2017 |
| 28029307 | Surgical Management of Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Pediatric and Wildtype GIST Clinic. | J Clin Oncol | 2017 |
| 27768921 | A simple and rapid UHPLC-MS/MS method for the quantitation of the dual aurora kinase A/B inhibitor SCH-1473759 in murine plasma. | J Pharm Biomed Anal | 2017 |
| 28350521 | Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis). | J Clin Oncol | 2017 |
| 29138631 | SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors. | Sarcoma | 2017 |
| 28674120 | Surveillance Recommendations for Children with Overgrowth Syndromes and Predisposition to Wilms Tumors and Hepatoblastoma. | Clin Cancer Res | 2017 |
| 28899971 | Matrix Screen Identifies Synergistic Combination of PARP Inhibitors and Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors in Ewing Sarcoma. | Clin Cancer Res | 2017 |